Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma

Inclusion Criteria: * Histologically or cytologically confirmed malignant brain tumor * Disease must be considered refractory to first line or relapsing after conventional therapy and for which no effective conventional treatment exists.· * Newly diagnosed, histologically proven brain stem glioma, except pilocytic astrocytomas. * Age: 1 to ≤ 21 years of age at study entry * Life expectancy: at least 8 weeks * ECOG Performance status ≤ 1 or Lansky-Play Scale\>= 70%, and including children with motor paresis due to disease * Measurable or evaluable disease * No other serious concomitant illness * No organ toxicity \> grade 2 NCI-CTC AE v3.0, except alopecia and neurological symptoms due to disease Exclusion Criteria: * Patients with spontaneous intratumoral hemorrhage will not be included in the study, in exception of small post-biopsy hemorrhage due to biopsy procedure * Pregnant and breast feeding woman * Uncontrolled intercurrent illness or active infection * Chemotherapy within 4 weeks prior to study medication (within 6 weeks, if the regimen contained a nitrosourea) * Radiation therapy within 6 weeks prior to study medication * Any clinical or non-clinical evidence of pulmonary dysfunction or pre-existing lung disease * Severe cardiac pathology; history of myocardial infarction within the year prior to inclusion * Any significant ophthalmologic abnormality, especially severe dry eye syndrome, keratoconjunctivitis sicca, Sjögren syndrome, severe exposure keratitis or any other disorder likely to increase the risk of corneal epithelial lesions * Treatment with Coumarin (warfarin)